Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer


Clinical Trial Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo an up to 7 day screening period to determine eligibility for study entry. On Day 0, patients who meet the eligibility requirements will be enrolled in an open-label manner and will receive a loading dose of teverelix TFA (one subcutaneous (SC) injection in the abdomen and one intramuscular (IM) injection in the buttock). Patients will then receive maintenance doses of teverelix TFA (one SC injection in the abdomen) at 4- or 6-weekly intervals up to week 24. The patients will return for a final assessment 4 weeks after their last maintenance dose injection. The initial dosing regimen to be tested (Group 1) is: Loading Dose = 120 mg teverelix TFA SC + 120 mg teverelix TFA IM Maintenance Dose = 120 mg teverelix TFA SC every 6 weeks If this dosing regimen is unsuccessful (more than 2 (of 20) patients fail treatment) then recruitment to Group 1 will end and enrollment in Group 2 will open. The dosing regimen that may be tested (Group 2) is: Loading Dose = 180 mg teverelix TFA SC + 180 mg teverelix TFA IM Maintenance Dose = 180 mg teverelix TFA SC every 6 weeks If this dosing regimen is unsuccessful (more than 6 (of 60) patients fail treatment) then recruitment to Group 2 will end and the study will be terminated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04693507
Study type Interventional
Source Antev Ltd.
Contact
Status Completed
Phase Phase 2
Start date March 4, 2021
Completion date February 6, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05687019 - Efficacy of Hyaluronic Acid Injections on Functional Recovery After Surgery for Prostate Adenoma N/A
Recruiting NCT02940977 - Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
Withdrawn NCT05157724 - Observational Study to Compare Two Prostate Laser Enucleation Techniques in Terms of Urinary Incontinence
Completed NCT02943070 - Rezum I Pilot Study for Benign Prostatic Hyperplasia N/A
Completed NCT02940392 - Rezum FIM Optimization Study N/A